Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19651226 | 0.95 | ELANE (0.52) | ELANEMEN1KMT2A | |
| SCHEMBL21796098 | 0.93 | ELANE (0.47) | ELANEPDE4BPDE4DMEN1KMT2A | |
| Benzene SCHEMBL19640020 | 0.92 | ELANE (0.46) | ELANEPDE4BPDE4DMEN1KMT2A | |
| SCHEMBL19640017 | 0.91 | ELANE (0.46) | ELANE | |
| SCHEMBL19656261 | 0.90 | ELANE (0.50) | ELANECCR2 | |
| SCHEMBL21796089 | 0.89 | ELANE (0.47) | ELANECCR2 | |
| SCHEMBL21796125 | 0.89 | ELANE (0.47) | ELANEMEN1KMT2A | |
| Benzene SCHEMBL19639965 | 0.89 | ELANE (0.47) | ELANECCR2 | |
| SCHEMBL19656243 | 0.89 | ELANE (0.50) | ELANE | |
| Benzene SCHEMBL19640015 | 0.89 | ELANE (0.46) | ELANEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340611-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | ELANE 2/4885CCR2 653/4885PDE4B 1353/4885 |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | SERPINB1, ELANE, EPX | ELANE 2/4885CCR2 1085/4885PDE4B 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.